Recurrent Malignant Uterine Corpus Neoplasm
5 clinical trials · Condition
◉ Watch Recurrent Malignant Uterine Corpus Neoplasm
| Record | Firm | Date |
|---|---|---|
| Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer (NCT03348631) | National Cancer Institute (NCI) | 2019-05-01 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (NCT02142803) | National Cancer Institute (NCI) | 2014-05-20 |
| Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (NCT01935934) | National Cancer Institute (NCI) | 2013-05-08 |
| Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (NCT00977574) | National Cancer Institute (NCI) | 2009-09-14 |
Track Recurrent Malignant Uterine Corpus Neoplasm automatically
Every clearance here is in the API, with alerts when new ones post.